ci-fGBD:在阿尔茨海默氏病中进行多模式数据聚类的集群集成快速通用化粗略分解
medRxiv : the preprint server for health sciences
|September 15, 2025
概括
一个新的矩阵因子化和集群框架,ci-fGBD (集群集成的快速通用化破碎分解),有效地对神经退行性疾病患者进行分层. 它整合了各种数据类型,以揭示具有临床意义的患者子组,并增强了可解释性.
科学领域:
- 生物医学数据科学是生物医学数据科学.
- 计算生物学是一种计算生物学.
- 神经科学是一个神经科学.
背景情况:
- 在神经退行性疾病中常见的多模式生物医学数据集,由于缺少数据,高维度和偏见,对患者分层构成挑战.
- 现有的集群方法通常需要大量的预处理,并且很难有效地整合异质数据类型.
研究的目的:
- 引入ci-fGBD (集群集成快速通用化突发性分解),这是一个新的框架,用于使用多式联络数据对异质患者群体进行分层.
- 开发一种原生处理区块结构,多模式数据集的方法,并协调跨不同数据类型的贡献.
主要方法:
- ci-fGBD是一个矩阵分解和集群框架,扩展了经典的布鲁哈分解.
- 它共同学习潜在的表示和患者集群,自动协调来自神经成像,认知评估,基因组学,可穿戴传感器和环境暴露的贡献.
主要成果:
- 对现实数据集的基准测试表明,ci-fGBD与标准方法相比具有更高的性能.
- 该框架始终在阿尔茨海默病队列中确定临床上有意义的子组.
- ci-fGBD捕捉了微妙的生物,认知和人口异质性,增强了可解释性和稳定性.
结论:
- ci-fGBD提供了一种可靠和可解释的解决方案,用于使用多式联络生物医学数据对复杂患者群体进行分层.
- 该框架有效地解决了神经退行性疾病研究中缺失的价值观,高维度和模式特定偏见所带来的挑战.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825


